A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model
International Journal of Molecular Sciences · 13.09.2025 · 26 (18) · 8937
DOI: 10.3390/ijms26188937 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.09.2025. Verfasst von Maria Antonietta Grignano und 20 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Nephrology, Dialysis and Transplantation, Fondazione I.R.C.C.S. Policlinico San Matteo, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: Kidney Transplantation, PCSK9 Inhibitors, Reperfusion Injury, Ischemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Italian Ministry of Health.
Abstract (Originalsprache)
Proprotein Convertase Subtilisin/Kexin type 9 PCSK9 inhibitors (PCSK9i) are a novel class of cholesterol-lowering agents that also offer protection against tissue ischemia by reducing apoptosis, pyroptosis, and myocardial infarct size. This study evaluated the effects of the PCSK9 inhibitor PEP 2-8 during hypothermic perfusion (HP) in a rat model of donation after circulatory death (DCD) kidney transplantation. DCD kidneys were perfused at 4 °C for six hours with either Perf-Gen solution alone (control) or Perf-Gen supplemented with PEP 2-8. Glucose and lactate dehydrogenase (LDH) levels were measured at baseline and after six hours (T6h). At T6h, kidneys were evaluated for ischemic injury, tubular cell proliferation, apoptosis, nitrotyrosine (N-Tyr) staining, tissue ATP and LDH levels, and gene expression of PCSK9 and NOX4. Metabolomic profiling was also performed. PEP 2-8 treatment significantly reduced PCSK9 expression, decreased tubular ischemic injury and necrosis, and lowered LDH release. Treated kidneys showed enhanced tubular cell proliferation, reduced apoptosis, and diminished oxidative stress, indicated by decreased N-Tyr staining and NOX4 expression. Energy metabolism was improved, with higher tissue ATP and glucose levels observed in the PEP 2-8 group. Metabolomic analysis further supported the antioxidant effects of PEP 2-8. This is the first study to demonstrate that PEP 2-8 administered during pre-transplant hypothermic perfusion provides renal protection by improving energy metabolism and reducing oxidative stress in the context of ischemic injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Nephrology, Dialysis and Transplantation, Fondazione I.R.C.C.S. Policlinico San Matteo, 27100 Pavia, Italy.
- Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy.
- Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, 16132 Genova, Italy.
- IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
- Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, 16132 Genova, Italy.
- Transplant Unit, Fondazione I.R.C.C.S. Policlinico San Matteo, 27100 Pavia, Italy.
ORCID-Profile: Maria Antonietta Grignano, Marilena Gregorini, Caterina Ivaldo, Noemi Rumeo, Simona Viglio, Paolo Iadarola, Tefik Islami, Eleonora Francesca Pattonieri, Gabriele Ceccarelli, Francesca Viazzi, Pasquale Esposito, Teresa Rampino
Förderung
- the Italian Ministry of Health
Zitieren
APA
Grignano, M. A., Gregorini, M., Barisione, C., Ivaldo, C., Verzola, D., Rumeo, N., Malabarba, S., Mimmi, M. C., Montatixe Fonseca, E. C., Viglio, S., Iadarola, P., Islami, T., Pattonieri, E. F., Ceccarelli, G., Picciotto, D., Pratesi, G., Viazzi, F., Stea, E. D., Arbustini, E., …, & Rampino, T. (2025). A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model. International Journal of Molecular Sciences, 26(18), 8937. https://doi.org/10.3390/ijms26188937
Vancouver
Grignano MA, Gregorini M, Barisione C, Ivaldo C, Verzola D, Rumeo N, et al. A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model. International Journal of Molecular Sciences. 2025;26(18):8937. doi:10.3390/ijms26188937
BibTeX
@article{Grignano2025,
author = {Grignano, Maria Antonietta and Gregorini, Marilena and Barisione, Chiara and Ivaldo, Caterina and Verzola, Daniela and Rumeo, Noemi and Malabarba, Stefano and Mimmi, Maria Chiara and Montatixe Fonseca, Elizabeth Carolina and Viglio, Simona and Iadarola, Paolo and Islami, Tefik and Pattonieri, Eleonora Francesca and Ceccarelli, Gabriele and Picciotto, Daniela and Pratesi, Giovanni and Viazzi, Francesca and Stea, Emma Diletta and Arbustini, Eloisa and Esposito, Pasquale and Rampino, Teresa},
title = {A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {18},
pages = {8937},
doi = {10.3390/ijms26188937}
}
EUVIMED